Neuralink said part of its brain implant malfunctioned in the weeks following its first in-human procedure

Neuralink-logo

Important Takeaways:

  • The company has built a brain-computer interface that could help patients with paralysis control external technologies with their minds.
  • Elon Musk’s startup Neuralink on Wednesday said part of its brain implant malfunctioned after it put the system in a human patient for the first time.
  • Neuralink has built a brain-computer interface, or a BCI, that could eventually help patients with paralysis control external technology using only their minds.
  • The company’s system, called the Link, records neural signals using 1,024 electrodes across 64 “threads” that are thinner than a human hair, according to its website.
  • In January, Neuralink implanted the device in a 29-year-old patient named Noland Arbaugh.
  • A number of threads have retracted from Arbaugh’s brain, Neuralink said in a blog post on Wednesday

Read the original article by clicking here.

Musk says Neuralink patient is now able to move a mouse with thoughts

Elon Musk

Important Takeaways:

  • The first human patient implanted with a brain-chip from Neuralink appears to have fully recovered and is able to control a computer mouse using their thoughts, the startup’s founder, Elon Musk, said late on Monday.
  • “Progress is good, and the patient seems to have made a full recovery, with no ill effects that we are aware of. Patient is able to move a mouse around the screen by just thinking,” Musk said in a Spaces event on the social media platform X.
  • The firm successfully implanted a chip on its first human patient last month, after receiving approval for human trial recruitment in September.
  • The study uses a robot to surgically place a brain-computer interface implant in a region of the brain that controls the intention to move, Neuralink has said, adding that the initial goal was to enable people to control a computer cursor or keyboard using their thoughts.
  • Musk has grand ambitions for Neuralink, saying it would facilitate speedy surgical insertions of its chip devices to treat conditions like obesity, autism, depression and schizophrenia.

Read the original article by clicking here.

Human Upgrade with brain chip implant: Neuralink’s goal to help people with debilitating conditions

Brain-Implant

Important Takeaways:

  • Elon Musk announced that his company Neuralink implanted a brain chip in a human in a preliminary clinical study. If research studies continue to look promising, devices like these could one day be a “game changer” for people with limited motor function, experts told ABC News.
  • Neuralink says its goal is to help people living with debilitating conditions, including paralysis, communicate and control external devices with their thoughts.
  • The patient who received the implant is “recovering well,” Musk said in a post on X Tuesday.
  • Musk’s company is not alone in developing this type of technology. In recent years, research teams from across the globe have announced early but promising studies of brain-machine interface devices.
  • Last year, Swiss researchers said they combined artificial intelligence and brain and spine implants to help a man paralyzed in a motorcycle accident walk again.
  • And a woman who had lost her voice to paralysis was able to have a conversation with her husband again, with the help of a mind-controlled avatar, the Swiss researchers said.

Read the original article by clicking here.

Neuralink raised $280 Million and recently received approval for human trials

Must Neuralink

Important Takeaways:

  • Elon Musk’s Neuralink Raises $280 Million to Develop Brain Implants
  • Neuralink Corp., Elon Musk’s brain-implant company, has raised $280 million in new funding from investors to develop its technology.
  • The startup announced the funding round in a post on Musk’s X social network, formerly known as Twitter. The deal was led by Founders Fund, a venture capital firm backed by billionaire Peter Thiel.
  • Neuralink is the best-known player in a growing field of brain technology companies. Partly spurred by Neuralink’s high profile, investors have backed dozens of other startups exploring similar technology.
  • One rival, Synchron Inc., enrolled its first patient in a US clinical trial last year, beating Neuralink to that milestone.
  • Neuralink recently received approval from the US Food and Drug Administration to conduct human clinical trials. The company is developing a small device that uses electrode-laced wires to link the brain to a computer. Placing the device requires drilling into the skull

Read the original article by clicking here.

Neuralink brain-chip gets DFA approval for first-in-human clinical studies

Brain Chip

Daniel 12:4 But you, Daniel, roll up and seal the words of the scroll until the time of the end. Many will go here and there to increase knowledge.”

Important Takeaways:

  • Elon Musk’s brain-chip company Neuralink gets FDA’s approval to start human trials that could help treat autism or obesity
  • Human trials are set to start soon for Elon Musk’s brain-chip implants after his company Neuralink gained FDA approval Thursday.
  • Neuralink posted on social media that the FDA had given the OK for the first-in-human clinical studies.
  • ‘Congratulations Neuralink team!,’ Musk Tweeted after the news.
  • The move is a milestone after Neuralink struggled to gain earlier approvals.
  • Musk’s plans for Neuralink have included the device helping both disabled and healthy people cure a range of conditions such as obesity, autism, depression and schizophrenia.
  • It could also allow for web browsing and telepathy.

Read the original article by clicking here.

Brain Chip 6 months out from being tested on Humans

Romans 1:25 “25 because they exchanged the truth about God for a lie and worshiped and served the creature rather than the Creator, who is blessed forever! Amen.

Important Takeaways:

  • Musk’s ‘brain chip’ could be tested on humans in 6 months
  • Billionaire Elon Musk has said that a wireless ‘brain chip’ developed by his company Neuralink could begin human clinical trials in six months.
  • The Neuralink device will first target restoring vision and enabling movement of muscles in people who cannot do so, Musk said.
  • Most recently, Neuralink has been conducting tests on animals as it seeks approval from the US Food and Drug Administration (FDA) to begin clinical trials in people.
  • He wants to develop a chip that would allow the brain to control complex electronic devices and eventually allow people with paralysis to regain motor function and treat brain diseases such as Parkinson’s, dementia and Alzheimer’s. He also wants to meld the brain with artificial intelligence.

Read the original article by clicking here.

Musk’s Neuralink venture promises to reveal a ‘working’ brain-computer device

By Tina Bellon

(Reuters) – Billionaire entrepreneur Elon Musk’s neuroscience startup Neuralink on Friday is expected to detail its latest innovations for implanting minuscule computer chips in human brains, fueling expectations among scientists who closely watch the company.

Co-founded by Musk in 2016, Neuralink aims to implant wireless brain-computer interfaces that include thousands of electrodes in the most complex human organ to help cure neurological conditions like Alzheimer’s, dementia and spinal cord injuries and ultimately fuse humanity with artificial intelligence.

The company said it will provide an update on its work during a live webcast late on Friday afternoon, with Musk tweeting that the presentation will include a “working Neuralink device.”

Musk, who frequently warns about the risks of artificial intelligence, is no stranger to revolutionizing industries as chief executive of electric vehicle company Tesla Inc and aerospace manufacturer SpaceX.

During a Neuralink presentation in July 2019, Musk said the company was aiming to receive regulatory approval to implant its device in human trials by the end of this year.

“This has a very good purpose, which is to cure important diseases — and ultimately to secure humanity’s future as a civilization relative to AI,” Musk said at the time.

The company promises to implant a sensor roughly eight millimeters in diameter, or smaller than a fingertip, potentially under only local anesthesia. With the help of a sophisticated robot, flexible threads or wires smaller than a human hair are implanted in brain areas responsible for motor and sensory functions.

Neuroscience experts said that while Neuralink’s mission to read and stimulate brain activity in humans is feasible, the company’s timeline appeared overly ambitious.

“Everyone in the field would be very impressed if they actually showed data from a device implanted in a human,” said Graeme Moffat, a neuroscience research fellow at the University of Toronto.

Small devices that electronically stimulate nerves and brain areas to treat hearing loss and Parkinson’s disease have been implanted in humans for decades.

Neuroscientists have also conducted brain implant trials with a small number of people who have lost control of bodily functions due to spiral cord injuries or neurological conditions like strokes. Humans in those trials could control robotic limbs or small objects, like a computer keyboard or mouse cursor, but have yet to complete more sophisticated tasks.

Most of the current cutting-edge research in brain-machine interface is conducted on animals, scientists note, with safety challenges and lengthy regulatory approval procedures preventing larger human trials.

Brain-machine interface science has had a surge in investment and business activity over the past five years, largely thanks to advancements in material, wireless and signaling technology.

But scientists still face a range of issues, including preventing tissue scarring around the implant, the quality of measurements and the development of machine-learning algorithms to interpret brain signals, said Amy Orsborn, an assistant professor at the University of Washington who researches neural interfaces.

“I don’t think we know what the magic bullet is, we only know the problem,” Orsborn told Reuters.

(Reporting by Tina Bellon in New York; Editing by Joe White and Dan Grebler)